A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
NEW YORK, Aug. 15, 2019 -- Delcath Systems, Inc. ("Delcath," the "Company", "we", "our" or "us" (OTCQB: DCTH)) today announced that it has entered into a definitive agreement for gross proceeds of approximately $9.5 million at a combined price of $1,000 per Unit. Each...
Seasoned leader with successful track record joins to help Delcath in the next phase of its development.NEW YORK, July 29, 2019 -- Delcath Systems, Inc. (OTC Pink: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver...
Retrospective Study by University Hospital of Tubingen Shows Median Overall Survival of 27.4 Months in Patients with Ocular Melanoma Liver MetastasesNEW YORK, July 22, 2019 -- Delcath Systems, Inc. (OTCPK: DCTH), an interventional oncology company focused on the...
NEW YORK, July 17, 2019 -- Delcath Systems, Inc. ("Delcath," the "Company", "we", "our" or "us" (OTCPK: DCTH) has closed on its previously announced private placement with gross proceeds of $20 million at a combined price of $1,000 per Unit. Each Unit consists of one...
NEW YORK, July 11, 2019 -- Delcath Systems, Inc. ("Delcath," the "Company", "we", "our" or "us") (OTCPK: DCTH) today announced that it has entered into a definitive agreement for gross proceeds of approximately $20 million at a combined price of $1,000 per Unit. Each...
Study by LUMC Shows Overall Survival of 20.3 Months in Patients with Ocular Melanoma Liver MetastasesNEW YORK, April 16, 2019 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
NEW YORK, Feb. 28, 2019 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, highlights the experiences of patients with ocular melanoma as part of Rare Disease Day®-a...
Discussions Underway With Potential Commercialization Partners NEW YORK, Feb. 11, 2019 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has...
NEW YORK, Feb. 08, 2019 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces an abstract from a prospective phase 2 study conducted in the Netherlands of the use...
7 Year Agreement with medac to Maximize Potential of CHEMOSAT in Europe Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S. NEW YORK, Dec. 26, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology...